Publication Name	World Journal of Ophthalmology
Manuscript ID	15609
Country	United Kingdom

Received	2014-12-01 09:45
Peer-Review Started	2014-12-01 19:48
To Make the First Decision	2015-01-20 13:35
Return for Revision	2015-01-22 15:15
Revised	2015-02-10 08:31
Second Decision	2015-03-24 16:54
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-04-07 16:17
Articles in Press	2015-04-07 16:17
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-04-27 16:04
Publish the Manuscript Online	2015-05-19 17:29

ISSN	2218-6239 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Ophthalmology
Manuscript Type	Review
Article Title	New treatments for diabetic macular edema
Manuscript Source	Invited Manuscript
All Author List	Farhan Husain Zaidi and Ejaz Ansari
Funding Agency and Grant Number
Corresponding Author	Farhan Husain Zaidi, PhD, FRCSs, FRCOphth, Department of Ophthalmology, Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Southwick Hill Road, Portsmouth, Hampshire PO6 3LY, United Kingdom. fhz12@hotmail.com
Key Words	Diabetic macular edema; Diabetic macular oedema; Triamcinolone; Anti-vascular endothelial growth factor agents; Steroids; Non-steroidal anti-inflammatory drugs; Biologicals; Protein kinase C inhibitors
Core Tip	Current evidence suggests the anti-vascular endothelial growth factor (anti-VEGF) agents aflibercept and ranibizumab are the most effective agents for most patients with diabetic macular edema. Aflibercept may be more effective when vision is very low. Other drugs retain niche roles including bevacizumab owing to lower costs, steroids like triamcinolone which can be effective many years later, dexamethasone and non-steroidal anti-inflammatory drugs like nepafenac. Also considered are anti-tumour necrosis factor agents like infliximab, anti-interleukins like canakinumab, anti-inflammatories including minocycline, rapamycin (sirolimus) and protein kinase C inhibitors midostaurin and ruboxistaurin. Fluocinolone implants, anti-VEGF agents bevasiranib and pegaptinib, cyclo-oxygenase-2 inhibitors like celecoxib, phospholipase A2 inhibitors and recombinant erythropoietin are discussed.
Publish Date	2015-05-19 17:29
Citation	Zaidi FH, Ansari E. New treatments for diabetic macular edema. World J Ophthalmol 2015; 5(2): 45-54
URL	http://www.wjgnet.com/2218-6239/full/v5/i2/45.htm
DOI	http://dx.doi.org/10.5318/wjo.v5.i2.45

Full Article (PDF)	WJO-5-45.pdf
Full Article (Word)	WJO-5-45.doc
Manuscript File	15609-Review.doc
Answering Reviewers	15609-Answering reviewers.pdf
Audio Core Tip	15609-Audio core tip.wav
Conflict-of-Interest Disclosure Form	15609-Conflict-of-interest statement.pdf
Copyright License Agreement	15609-Copyright assignment.pdf
Peer-review Report	15609-Peer-review(s).pdf
Scientific Misconduct Check	15609-Scientific misconduct check.pdf
Scientific Editor Work List	15609-Scientific editor work list.pdf